ALLOHA
Live / Applied — First extension granted (statement of use) (as of 02 Dec 2025)
What this means for you
Not registered yet, but its 24 May 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98568310
- Mark type
- Stylized text
- Filed
- 24 May 2024
- Published for opposition
- 15 Apr 2025
- Attorney of record
- Tiffany D. Gehrke
Goods and services
- Class 005 — Pharmaceuticals: Cells for medical or clinical use for use in the treatment of cancer; pharmaceutical and biopharmaceutical T-cell receptor engineered preparations for use in the treatment of cancer; T-cell therapy products, namely, T-cell receptor engineered cells for medical use in the treatment of cancer
- Class 042 — Scientific and technological services: Pharmaceutical research and development in the field of T-cell therapy for the treatment of cancer; T-cell therapy research services, namely, pharmaceutical and scientific research in the field of treatment of cancer using T-cell receptor engineered T-cell therapies
Owner
- TScan Therapeutics, Inc., Waltham, MA, US
- TScan Therapeutics, Inc., Waltham, MA, US
Prosecution history
- 03 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 02 Dec 2025 — SOU EXTENSION 1 GRANTED
- 02 Dec 2025 — SOU EXTENSION 1 FILED
- 02 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 10 Jun 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 15 Apr 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 15 Apr 2025 — PUBLISHED FOR OPPOSITION
- 09 Apr 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 21 Mar 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 21 Mar 2025 — EXAMINER'S AMENDMENT ENTERED
- 21 Mar 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 21 Mar 2025 — EXAMINERS AMENDMENT E-MAILED
- 21 Mar 2025 — EXAMINERS AMENDMENT -WRITTEN
- 14 Feb 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 13 Feb 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE